Top

Published in:

01-04-2014 | Research Article

Prognostic role of microRNA-100 in various carcinomas: evidence from six studies

Authors: Jie Chen, Biqiang Zheng, Chunmeng Wang, Yong Chen, Chunyan Du, Guangfa Zhao, Ye Zhou, Yingqiang Shi

Published in: Tumor Biology | Issue 4/2014

Abstract

Recent studies have shown that microRNAs (miRNA) exhibit altered expression levels in cancers, and they may be considered as valuable prognostic biomarkers for patients with cancers. We performed this meta-analysis to provide a comprehensive evaluation of the role of miRNA-100 expression on the overall survival rate by calculating the pooled hazard ratio (HR) for overall survival (OS), which compared the high and low expression levels of miR-100 in patients of the available studies. Finally, a total of six studies dealing with various carcinomas were involved for this meta-analysis. The results indicated that lower expression of miR-100 in cancerous tissue could significantly predict poorer survival in various carcinomas with the pooled HR of 2.19 (95 % CI 1.49–3.24, P = 0.0007). In conclusion, the findings from this present meta-analysis suggest that miR-100 expression is associated with OS in cancer patients and could be a useful clinical prognostic factor for those patients.

Yang W, Lee DY, Ben-David Y. The roles of microRNAs in tumorigenesis and angiogenesis. Int J Physiol Pathophysiol Pharmacol. 2011;3:140–55.PubMedCentralPubMed

Osman A. MicroRNAs in health and disease—basic science and clinical applications. Clin Lab. 2012;58:393–402.PubMed

Roberts AP, Lewis AP, Jopling CL. The role of microRNAs in viral infection. Prog Mol Biol Transl Sci. 2011;102:101–39.PubMedCrossRef

Zheng B, Liang L, Huang S, Zha R, Liu L, Jia D, et al. Microrna-409 suppresses tumour cell invasion and metastasis by directly targeting radixin in gastric cancers. Oncogene. 2012;31:4509–16.PubMedCrossRef

Zheng B, Liang L, Wang C, Huang S, Cao X, Zha R, et al. Microrna-148a suppresses tumor cell invasion and metastasis by downregulating rock1 in gastric cancer. Clin Cancer Res. 2011;17:7574–83.PubMedCrossRef

Berardi E, Pues M, Thorrez L, Sampaolesi M. MiRNAs in ESC differentiation. Am J Physiol Heart Circ Physiol. 2012;303:H931–9.PubMedCrossRef

Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring, and therapeutics. A comprehensive review. EMBO Mol Med. 2012;4:143–59.PubMedCentralPubMedCrossRef

Roy S, Sen CK. MiRNA in wound inflammation and angiogenesis. Microcirculation. 2012;19:224–32.PubMedCentralPubMedCrossRef

Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol. 2012;6:590–610.PubMedCrossRef

10.

Huang L, Lin JX, Yu YH, Zhang MY, Wang HY, Zheng M. Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis, and poor prognosis in small cell carcinoma of the cervix. PLoS One. 2012;7:e33762.PubMedCentralPubMedCrossRef

11.

Liu J, Lu KH, Liu ZL, Sun M, De W, Wang ZX. Microrna-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1. BMC Cancer. 2012;12:519.PubMedCentralPubMedCrossRef

12.

Peng DX, Luo M, Qiu LW, He YL, Wang XF. Prognostic implications of microrna-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep. 2012;27:1238–44.PubMedCentralPubMed

13.

Wang S, Xue S, Dai Y, Yang J, Chen Z, Fang X, et al. Reduced expression of microrna-100 confers unfavorable prognosis in patients with bladder cancer. Diagn Pathol. 2012;7:159.PubMedCentralPubMedCrossRef

14.

Chen P, Zhao X, Ma L. Downregulation of microrna-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma. Mol Cell Biochem. 2013;383:49–58.PubMedCrossRef

15.

Wang G, Chen L, Meng J, Chen M, Zhuang L, Zhang L. Overexpression of microrna-100 predicts an unfavorable prognosis in renal cell carcinoma. Int Urol Nephrol. 2013;45:373–9.PubMedCrossRef

16.

Bai J, Guo A, Hong Z, Kuai W. Upregulation of microrna-100 predicts poor prognosis in patients with pediatric acute myeloid leukemia. Onco Targets Ther. 2012;5:213–9.PubMedCentralPubMed

17.

Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2007;26:53–77.PubMedCrossRef

18.

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.PubMedCentralPubMedCrossRef

19.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCentralPubMedCrossRef

20.

Zhang Y, Wang Z, Chen M, Peng L, Wang X, Ma Q, et al. Microrna-143 targets macc1 to inhibit cell invasion and migration in colorectal cancer. Mol Cancer. 2012;11:23.PubMedCentralPubMedCrossRef

21.

Hong L, Han Y, Li S, Yang J, Zheng J, Zhang H, et al. The malignant phenotype-associated microRNA in gastroenteric, hepatobiliary, and pancreatic carcinomas. Expert Opin Biol Ther. 2010;10:1693–701.PubMedCrossRef

22.

Lee S, Vasudevan S. Post-transcriptional stimulation of gene expression by microRNAs. Adv Exp Med Biol. 2013;768:97–126.PubMedCrossRef

23.

Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of cancer. Semin Oncol. 2011;38:724–33.PubMedCrossRef

24.

Liu J, Zheng M, Tang YL, Liang XH, Yang Q. MicroRNAs, an active and versatile group in cancers. Int J Oral Sci. 2011;3:165–75.PubMedCentralPubMedCrossRef

25.

Zeng Y, Qu X, Li H, Huang S, Wang S, Xu Q, et al. MicroRNA-100 regulates osteogenic differentiation of human adipose-derived mesenchymal stem cells by targeting bmpr2. FEBS Lett. 2012;586:2375–81.PubMedCrossRef

26.

Shi W, Alajez NM, Bastianutto C, Hui AB, Mocanu JD, Ito E, et al. Significance of plk1 regulation by mir-100 in human nasopharyngeal cancer. Int J Cancer. 2010;126:2036–48.PubMed

27.

Oliveira JC, Brassesco MS, Morales AG, Pezuk JA, Fedatto PF, da Silva GN, et al. MicroRNA-100 acts as a tumor suppressor in human bladder carcinoma 5637 cells. Asian Pac J Cancer Prev. 2011;12:3001–4.PubMed

28.

Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih IM, Zhang Y, et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One. 2008;3:e2436.PubMedCentralPubMedCrossRef

Title: Prognostic role of microRNA-100 in various carcinomas: evidence from six studies
Authors: Jie Chen
Biqiang Zheng
Chunmeng Wang
Yong Chen
Chunyan Du
Guangfa Zhao
Ye Zhou
Yingqiang Shi
Publication date: 01-04-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1398-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

Meta-analysis: eating frequency and risk of colorectal cancer

MDM2 SNP309 is an ethnicity-dependent risk factor for digestive tract cancers

Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer

The microRNA networks of TGFβ signaling in cancer

The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases

Absent expression of FLNA is correlated with poor prognosis of nasopharyngeal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer